• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial.

作者信息

Khan Laibah Arshad, Khan Muhammad Shahzeb, Ambrosy Andrew P, Greene Stephen J

机构信息

Department of Medicine, King Edward Medical University, Lahore, 54000, Pakistan.

Division of Cardiology, Duke University School of Medicine, Duke University Medical Center, Durham, NC, 27705, USA.

出版信息

Heart Fail Rev. 2024 Sep;29(5):1157-1160. doi: 10.1007/s10741-024-10427-5. Epub 2024 Jul 25.

DOI:10.1007/s10741-024-10427-5
PMID:39052147
Abstract
摘要

相似文献

1
Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial.选择性醛糖还原酶抑制作为糖尿病性心肌病的一种治疗方法：ARISE-HF试验总结
Heart Fail Rev. 2024 Sep;29(5):1157-1160. doi: 10.1007/s10741-024-10427-5. Epub 2024 Jul 25.
2
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.随机选择醛糖还原酶抑制剂治疗糖尿病心肌病患者的临床试验。
J Am Coll Cardiol. 2024 Jul 9;84(2):137-148. doi: 10.1016/j.jacc.2024.03.380. Epub 2024 Apr 8.
3
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.醛糖还原酶抑制作用稳定心力衰竭患者运动能力的临床试验（ARISE-HF）的原理和设计：高危糖尿病心肌病患者。
Am Heart J. 2023 Feb;256:25-36. doi: 10.1016/j.ahj.2022.11.003. Epub 2022 Nov 11.
4
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.醛糖还原酶抑制减轻糖尿病心肌病，并与心肌脂肪酸氧化减少相关。
Cardiovasc Diabetol. 2023 Mar 28;22(1):73. doi: 10.1186/s12933-023-01811-w.
5
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.用于治疗糖尿病性多发性神经病的醛糖还原酶抑制剂。
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD004572. doi: 10.1002/14651858.CD004572.pub2.
6
Aldose reductase / polyol inhibitors for diabetic retinopathy.醛糖还原酶/多元醇抑制剂治疗糖尿病视网膜病变。
Curr Pharm Biotechnol. 2011 Mar 1;12(3):373-85. doi: 10.2174/138920111794480642.
7
Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.醛糖还原酶和醛脱氢酶抑制剂结合位点的结构特征。
Mol Vis. 1998 Sep 29;4:19.
8
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?2004年醛糖还原酶抑制剂在糖尿病神经病变治疗中的现状如何？
Curr Diab Rep. 2004 Dec;4(6):405-8. doi: 10.1007/s11892-004-0047-z.
9
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.紫穗槐通过醛糖还原酶抑制活性对糖尿病性白内障的保护作用。
Biomed Pharmacother. 2016 Oct;83:221-228. doi: 10.1016/j.biopha.2016.05.018. Epub 2016 Jun 30.
10
Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.醛糖还原酶抑制剂与糖尿病治疗的纳米递药系统。
Mini Rev Med Chem. 2012 Apr;12(4):326-36. doi: 10.2174/138955712799829294.

本文引用的文献

1
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.随机选择醛糖还原酶抑制剂治疗糖尿病心肌病患者的临床试验。
J Am Coll Cardiol. 2024 Jul 9;84(2):137-148. doi: 10.1016/j.jacc.2024.03.380. Epub 2024 Apr 8.
2
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.特征化糖尿病性心肌病：ARISE-HF 试验的基线结果。
Cardiovasc Diabetol. 2024 Feb 1;23(1):49. doi: 10.1186/s12933-024-02135-z.
3
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
《2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》2023年聚焦更新
Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
4
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.醛糖还原酶抑制作用稳定心力衰竭患者运动能力的临床试验（ARISE-HF）的原理和设计：高危糖尿病心肌病患者。
Am Heart J. 2023 Feb;256:25-36. doi: 10.1016/j.ahj.2022.11.003. Epub 2022 Nov 11.
5
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.心力衰竭：糖尿病被低估的并发症。美国糖尿病协会共识报告。
Diabetes Care. 2022 Jul 7;45(7):1670-1690. doi: 10.2337/dci22-0014.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
7
The Pathophysiological Basis of Diabetic Cardiomyopathy Development.糖尿病心肌病发病机制的基础。
Curr Probl Cardiol. 2022 Sep;47(9):101156. doi: 10.1016/j.cpcardiol.2022.101156. Epub 2022 Feb 19.
8
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.GLP-1 受体激动剂在 2 型糖尿病患者中的心血管、死亡率和肾脏结局：随机试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213-8587(21)00203-5. Epub 2021 Aug 20.
9
Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction.糖尿病性心肌病：射血分数保留的B期心力衰竭的一种表现。
Diab Vasc Dis Res. 2015 Jul;12(4):234-8. doi: 10.1177/1479164115579006. Epub 2015 Apr 23.
10
Aldose reductase, oxidative stress, and diabetic mellitus.醛糖还原酶、氧化应激与糖尿病
Front Pharmacol. 2012 May 9;3:87. doi: 10.3389/fphar.2012.00087. eCollection 2012.